title: [Efficiency of radiation or chemoradiation therapy for diffusely growing brainstem tumors in children].
abstract: Radiation or chemoradiation therapy was performed in 97 children with diffusely growing brainstem tumors. A reduction in the severity of neurological disorders was achieved in 92 (94.8%) patients. The course of the disease was traced in 79 patients. Control studies recorded no complete tumor regression. Following 4-8 months, there was growth resumption of a tumor with its lysis and cyst formation in most children. The principal cause of death was local tumor progression. Six-month survivors were 64 (81%) patients; one-, two-, and three-survivors were 21 (26.5%), 8 (10.1%), and 3 (7.65) patients, respectively; one (2.8%) patient survived 5 years. A combination of radiotherapy and monochemotherapy with temodal, vincristine, oncofer, and theraloc failed to improve immediate and long-term results
authors.forename: O I
authors.initials: OI
authors.lastname: Shcherbenko
authors.forename: E V
authors.initials: EV
authors.lastname: Govorina
authors.forename: N I
authors.initials: NI
authors.lastname: Zelinskaia
authors.forename: R A
authors.initials: RA
authors.lastname: Parkhomenko
authors.forename: E V
authors.initials: EV
authors.lastname: Abbasova
authors.forename: M V
authors.initials: MV
authors.lastname: Rodionov
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D020295:Brain Stem Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002648:Child; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D000077204:Temozolomide; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014750:Vincristine; C501466:nimotuzumab; D003606:Dacarbazine; D000077204:Temozolomide